Arabic Arabic English English French French German German
dark

Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China

–This bridging study to select doses for the Phase II trial in China in patients with chronic hepatitis B (CHB)
–ASC42 clinical trials are being conducted in the U.S. and China for non-alcoholic steatohepatitis (NASH) and CHB. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Hillstream BioPharma Expands the Scientific Advisory Board with the Addition of Leading Innovator in the Study of Ferroptosis and Cancer, Scott Dixon, Ph.D.

Next Post

Centene Announces Organizational Enhancements, Establishes The Office Of The President

Related Posts
Total
0
Share